Myeloid ampk signaling restricts fibrosis but is not required for metformin improvements during cdahfd-induced nash in mice

HIGHLIGHTS

• What: Given that lower dosing of metformin (50 mpk) failed to activate AMPK signaling, the authors focused the characterization of NASH measures on the group receiving the higher, yet still physiological (250 mpk) dose of metformin . The authors provide evidence that endogenous myeloid AMPK signaling restricts the development of fibrosis Fig 1. The study design did not integrate control mice that express only Cre recombinase.
• Who: Julia R C Nunes and collaborators from the DepartmentUniversity of ON, Canada have published the research: Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.